Document is current
Any future updates will be listed below
-
Authors
Dettling, Angela https://orcid.org/0000-0003-0992-0236
Huber, Kurt
Kristensen, Steen D.
Aradi, Daniel
Schrage, Benedikt
Clemmensen, Peter
-
Funding
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
- License Information
-
More Information
Article History
Received: 8 August 2024
Accepted: 9 February 2025
First Online: 4 March 2025
Declarations
:
: SDK is National Coordinating Investigator of SOS-AMI (selatogrel, Idorsia) in Denmark and has received speaker fee from Chiesi (cangrelor). KH is National Coordinator Investigsator of SOS-AMI (selatogrel, Idorsia) in Austira. BS has received speaker fees from Abbott, Abiomed and AstraZeneca as well as research funding from Abiomed, the DFG and the EKFS; outside of the submitted work. PC has previously or currently been involved in research contracts, consulting, speakers bureau or received research and educational grants from: Abbott, AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli-Lilly, Evolva, Fibrex, Idorsia, Janssen, Merck, Myogen, Medtronic, Mitsubishi Pharma, The Medicines Company, Nycomed, Organon, Pfizer, Pharmacia, Philips, Regado, Sanofi, Searle, Servier, ViFor Pharma. The other authors have no conflicts of interest to declare.
